478 related articles for article (PubMed ID: 33125153)
21. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Eustace AJ; Crown J; Clynes M; O'Donovan N
J Transl Med; 2008 Sep; 6():53. PubMed ID: 18823558
[TBL] [Abstract][Full Text] [Related]
23. Disulfiram Synergizes with SRC Inhibitors to Suppress the Growth of Pancreatic Ductal Adenocarcinoma Cells in Vitro and in Vivo.
Li Z; Xie X; Tan G; Xie F; Liu N; Li W; Sun X
Biol Pharm Bull; 2021; 44(9):1323-1331. PubMed ID: 34471060
[TBL] [Abstract][Full Text] [Related]
24. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer.
Yonesaka K; Kudo K; Nishida S; Takahama T; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Okamoto I; Nishio K; Nakagawa K
Oncotarget; 2015 Oct; 6(32):33602-11. PubMed ID: 26418897
[TBL] [Abstract][Full Text] [Related]
25. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.
Huguet F; Fernet M; Giocanti N; Favaudon V; Larsen AK
Target Oncol; 2016 Jun; 11(3):371-81. PubMed ID: 26668065
[TBL] [Abstract][Full Text] [Related]
26. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
[TBL] [Abstract][Full Text] [Related]
27. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
28. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
29. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
31. Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells.
Wei J; Ma L; Li C; Pierson CR; Finlay JL; Lin J
Curr Cancer Drug Targets; 2019; 19(7):571-582. PubMed ID: 30332965
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.
Ma L; Wei J; Su GH; Lin J
Cancer Biol Ther; 2019; 20(6):855-865. PubMed ID: 30866697
[TBL] [Abstract][Full Text] [Related]
33. Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Er JL; Goh PN; Lee CY; Tan YJ; Hii LW; Mai CW; Chung FF; Leong CO
Apoptosis; 2018 Jun; 23(5-6):343-355. PubMed ID: 29740790
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
36. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
[TBL] [Abstract][Full Text] [Related]
37. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
[TBL] [Abstract][Full Text] [Related]
38. Response to combined molecular targeting: defining the role of P-STAT3.
Egloff AM; Grandis JR
Clin Cancer Res; 2011 Feb; 17(3):393-5. PubMed ID: 21266530
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells.
Wang M; Yuang-Chi Chang A
Oncotarget; 2018 Mar; 9(23):16533-16546. PubMed ID: 29662665
[TBL] [Abstract][Full Text] [Related]
40. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
Ahn K; O YM; Ji YG; Cho HJ; Lee DH
Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]